A resistance line and an ascending support line has formed in the chart of Amicus Therapeutics Inc. (NASDAQ:FOLD). If the stock breaks through this resistance level, a breakout...
BTIG analyst Yun Zhong reiterated a Buy rating on Amicus (NASDAQ:FOLD) Therapeutics on Wednesday, setting a price target of $15, which is approximately 47.20% above the present...
Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Amicus (NASDAQ:FOLD) Therapeutics on Friday, setting a price target of $14, which is approximately 39.17% above the...
Amicus (NASDAQ:FOLD) Therapeutics FOLD shares rallied 6.4% in the last trading session to close at $10.13. This move can be attributable to notable volume with a higher number of...
Immunovant (NASDAQ:IMVT), Inc. IMVT reported a net loss of 35 cents per share in the second quarter of fiscal 2022 (ended Sep 30, 2021), wider than the Zacks Consensus Estimate of...
Amicus (NASDAQ:FOLD) Therapeutics, Inc. FOLD has announced its intent to spin-off its gene therapy business and form a next-generation genetic medicine company, Caritas...
Amicus Therapeutics, Inc. is a biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Neutral | Neutral | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Buy | Strong Sell |
| Summary | Strong Sell | Strong Sell | Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.13 | 8.32 | 8.04 | -0.04 | -0.49% | 7.01M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 1.09 | 1.12 | 1.065 | 0.0000 | 0.00% | 9.44M | NYSE | |||
| 37.51 | 37.67 | 36.25 | +1.17 | +3.22% | 8.44M | NYSE | |||
| 0.1727 | 0.185 | 0.1668 | -0.0056 | -3.14% | 2.30M | NYSE | |||
| 0.34 | 0.354 | 0.201 | 0.000 | 0.00% | 0.00 | OTC Markets | |||
| 94.24 | 98.17 | 93.08 | -0.88 | -0.93% | 130.55M | NASDAQ | |||
| 3.60 | 3.79 | 3.52 | -0.180 | -4.76% | 150.44K | NYSE | |||
| 0.0001 | 0.0001 | 0.0001 | 0.0000 | 0.00% | 0.00 | OTC Markets | |||
| 0.0001 | 0.0001 | 0.0001 | 0.0000 | 0.00% | 0.00 | OTC Markets | |||
| 112.60 | 113.44 | 111.56 | -0.41 | -0.36% | 5.63M | NYSE | |||
| 0.269 | 0.269 | 0.269 | 0.0000 | 0.00% | 0.00 | OTC Markets | |||
| 0.00 | 0.00 | 0.00 | 0.0000 | 0.00% | 0.00 | OTC Markets | |||
| 17.49 | 27.85 | 17.10 | -10.600 | -37.74% | 1.09M | NYSE | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | OTC Markets |